PMC:7252008 / 3543-3994 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"97","span":{"begin":154,"end":159},"obj":"Gene"},{"id":"99","span":{"begin":197,"end":211},"obj":"Disease"},{"id":"100","span":{"begin":293,"end":311},"obj":"Disease"},{"id":"101","span":{"begin":340,"end":356},"obj":"Disease"},{"id":"102","span":{"begin":423,"end":432},"obj":"Disease"},{"id":"105","span":{"begin":175,"end":180},"obj":"CellLine"}],"attributes":[{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"Gene:3570"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"MESH:D001171"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"MESH:C000657245"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"MESH:D007153"},{"id":"A102","pred":"tao:has_database_id","subj":"102","obj":"MESH:D007239"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"CVCL:4140"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ID-19 pneumonia certainly do not detract from the use of the terminology “MAS-like” [8].\n.To conclude, we do not think that the lessons on the benefit of IL-6R antagonisms in CAR-T cell therapy or Stills disease, both in the setting of full immunocompetence, can be extrapolated to the severe COVID-19 pneumonia, in the setting of relative immunodeficiency, where vigorous cytokine response may be required to help control infection. The entire commun"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T24","span":{"begin":181,"end":185},"obj":"Body_part"},{"id":"T25","span":{"begin":373,"end":381},"obj":"Body_part"}],"attributes":[{"id":"A24","pred":"fma_id","subj":"T24","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A25","pred":"fma_id","subj":"T25","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"ID-19 pneumonia certainly do not detract from the use of the terminology “MAS-like” [8].\n.To conclude, we do not think that the lessons on the benefit of IL-6R antagonisms in CAR-T cell therapy or Stills disease, both in the setting of full immunocompetence, can be extrapolated to the severe COVID-19 pneumonia, in the setting of relative immunodeficiency, where vigorous cytokine response may be required to help control infection. The entire commun"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T42","span":{"begin":6,"end":15},"obj":"Disease"},{"id":"T43","span":{"begin":74,"end":77},"obj":"Disease"},{"id":"T44","span":{"begin":197,"end":211},"obj":"Disease"},{"id":"T45","span":{"begin":293,"end":301},"obj":"Disease"},{"id":"T46","span":{"begin":302,"end":311},"obj":"Disease"},{"id":"T47","span":{"begin":340,"end":356},"obj":"Disease"},{"id":"T48","span":{"begin":423,"end":432},"obj":"Disease"}],"attributes":[{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0015545"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0019434"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0021094"},{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"ID-19 pneumonia certainly do not detract from the use of the terminology “MAS-like” [8].\n.To conclude, we do not think that the lessons on the benefit of IL-6R antagonisms in CAR-T cell therapy or Stills disease, both in the setting of full immunocompetence, can be extrapolated to the severe COVID-19 pneumonia, in the setting of relative immunodeficiency, where vigorous cytokine response may be required to help control infection. The entire commun"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T27","span":{"begin":175,"end":178},"obj":"http://purl.obolibrary.org/obo/CLO_0002199"},{"id":"T28","span":{"begin":179,"end":185},"obj":"http://purl.obolibrary.org/obo/CL_0000084"}],"text":"ID-19 pneumonia certainly do not detract from the use of the terminology “MAS-like” [8].\n.To conclude, we do not think that the lessons on the benefit of IL-6R antagonisms in CAR-T cell therapy or Stills disease, both in the setting of full immunocompetence, can be extrapolated to the severe COVID-19 pneumonia, in the setting of relative immunodeficiency, where vigorous cytokine response may be required to help control infection. The entire commun"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T26","span":{"begin":154,"end":156},"obj":"Chemical"}],"attributes":[{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A27","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"ID-19 pneumonia certainly do not detract from the use of the terminology “MAS-like” [8].\n.To conclude, we do not think that the lessons on the benefit of IL-6R antagonisms in CAR-T cell therapy or Stills disease, both in the setting of full immunocompetence, can be extrapolated to the severe COVID-19 pneumonia, in the setting of relative immunodeficiency, where vigorous cytokine response may be required to help control infection. The entire commun"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T14","span":{"begin":154,"end":159},"obj":"http://purl.obolibrary.org/obo/GO_0004915"}],"text":"ID-19 pneumonia certainly do not detract from the use of the terminology “MAS-like” [8].\n.To conclude, we do not think that the lessons on the benefit of IL-6R antagonisms in CAR-T cell therapy or Stills disease, both in the setting of full immunocompetence, can be extrapolated to the severe COVID-19 pneumonia, in the setting of relative immunodeficiency, where vigorous cytokine response may be required to help control infection. The entire commun"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T7","span":{"begin":6,"end":15},"obj":"Phenotype"},{"id":"T8","span":{"begin":302,"end":311},"obj":"Phenotype"},{"id":"T9","span":{"begin":340,"end":356},"obj":"Phenotype"}],"attributes":[{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002721"}],"text":"ID-19 pneumonia certainly do not detract from the use of the terminology “MAS-like” [8].\n.To conclude, we do not think that the lessons on the benefit of IL-6R antagonisms in CAR-T cell therapy or Stills disease, both in the setting of full immunocompetence, can be extrapolated to the severe COVID-19 pneumonia, in the setting of relative immunodeficiency, where vigorous cytokine response may be required to help control infection. The entire commun"}